Mohammed Bayasi, MD
Pulmonary Disease · Grand Blanc, MINPI 1528170073
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,375 of the $126,931 with a category attached, or 87.7%. GSK accounts for 89.7% of it on its own, with 44 other manufacturers making up the rest. Reporting peaked in 2023 at $39,109 and has fallen 95.8% since, to $1,632 in 2025. Among pulmonary disease clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 559 payments — averaging $227.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$114K
- Viiv Healthcare Company$3K
- Pulmonx Corporation$1K
- AstraZeneca$1K
- Jazz Pharmaceuticals Inc.$623
- Boehringer Ingelheim$579
- plus $6K from 39 others
Across 2 payments — averaging $588.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim Canada Ltd.ltee$1K
What the payments were for
- Speaking & faculty fees$111,37588%
- Travel & lodging$3,1712%
- Food & beverage$12,14510%
- Education$2390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$50,000
- NUCALA$10,245
- ANORO$1,161
- Pulmonx Endobronchial Valve EBV$952
- CHARTIS CATHETER$321
- ZEPHYR ENDOBRONCHIAL VALVE$321
- ZEPHYR DELIVERY CATHETER$321
- PULMONX CHARTIS TABLET CONSOLE$321
- XYWAV$265
- AREXVY$243
- Blue Rhino$200
- UPTRAVI$126
- OPSUMIT$126
- PARADISE RENAL DENERVATION SYSTEM$125
- SUNOSI$115
- BREZTRI$107
How this compares
$126,931 in reported general payments places this provider in the 95th percentile of 463 pulmonary disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 429 | $522,122 |
| OpsumitMacitentan | 24 | $305,236 |
| OfevNintedanib Esylate | 13 | $174,174 |
| AdempasRiociguat | 12 | $169,052 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $104,666 |
| XolairOmalizumab | 29 | $69,060 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $56,171 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $52,585 |
| Dupixent PenDupilumab | 13 | $47,594 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 74 | $36,201 |
| NeuproRotigotine | 16 | $32,371 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 99 | $28,830 |
| EliquisApixaban | 26 | $28,515 |
| XareltoRivaroxaban | 15 | $23,172 |
| Spiriva HandihalerTiotropium Bromide | 14 | $19,991 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $113,864 | $611,059550 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $576 | $305,23624 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $579 | $212,03259 claims |
| BayerAdempas | $178 | $169,05212 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,373 | $74,79194 claims |
| Johnson & JohnsonXarelto | $98 | $23,17215 claims |
| MerckDulera | $51 | $12,45921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 463 pulmonary disease providers in Michigan.
Other pulmonary disease in Grand Blanc
- Meilan HanAnn Arbor$779K
- Njira LugogoAnn Arbor$741K
- Gustavo Cumbo NacheliGrand Rapids$724K
- Gary FergusonLivonia$601K
- Justin OldhamAnn Arbor$392K
- Mounir GhaliWyoming$371K
- Kevin FlahertyAnn Arbor$328K
- Podduturu ReddyPort Huron$324K
- Samuel AllenTroy$287K
- Daniel MaxwellAlpena$235K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.